Showing results (111-120 of 126) with videos related to
Sort By:
Pageof 13
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 19, 2020
Prediction of early recurrence of hepatocellular carcinoma after resection using digital pathology images assessed by machine learningAkira Saito, Hidenori Toyoda, Masaharu Kobayashi, et al.British Journal of Cancer|March 6, 2019
Phase III randomised trial comparing 6 vs. 12-month of capecitabine as adjuvant chemotherapy for patients with stage III colon cancer: final results of the JFMC37-0801 studyNaohiro Tomita, Katsuyuki Kunieda, Atsuyuki Maeda, et al.The American Journal of Surgical Pathology|September 2, 2020
Optimal Criteria for G3 (Poorly Differentiated) Stage II Colon Cancer: Prospective Validation in a Randomized Controlled Study (SACURA Trial)Hideki Ueno, Megumi Ishiguro, Eiji Nakatani, et al.ESMO Open|November 15, 2018
Updated 5-year survival and exploratory T x N subset analyses of ACTS-CC trial: a randomised controlled trial of S-1 versus tegafur-uracil/leucovorin as adjuvant chemotherapy for stage III colon cancerTetsuya Kusumoto, Megumi Ishiguro, Eiji Nakatani, et al.Annals of Surgery|January 24, 2019
Liver Resection for Multiple Hepatocellular Carcinomas: A Japanese Nationwide SurveyYasuyuki Fukami, Yuji Kaneoka, Atsuyuki Maeda, et al.The British Journal of Surgery|November 15, 2022
Tranexamic acid and blood loss in pancreaticoduodenectomy: TAC-PD randomized clinical trialKenta Ishii, Yukihiro Yokoyama, Yoshihiko Yonekawa, et al.Clinical Colorectal Cancer|December 19, 2017
Planned Safety Analysis of the ACTS-CC 02 Trial: A Randomized Phase III Trial of S-1 With Oxaliplatin Versus Tegafur and Uracil With Leucovorin as Adjuvant Chemotherapy for High-Risk Stage III Colon CancerTetsuya Kusumoto, Eiji Sunami, Mitsuyoshi Ota, et al.European Journal of Cancer (Oxford, England : 1990)|April 21, 2018
A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafur-uracil versus surgery alone in stage II colon cancer: SACURA trialChu Matsuda, Megumi Ishiguro, Satoshi Teramukai, et al.Journal of Gastroenterology|April 16, 2026
Usefulness of an S-1 dosage formula for predicting adverse events in adjuvant chemotherapy for curatively resected pancreatic cancer: an exploratory analysis of the randomized clinical trial (JASPAC-01)Kazunaga Ishigaki, Yousuke Nakai, Kousuke Kashiwabara, et al.Annals of Surgical Oncology|December 26, 2025
High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1Keizo Fujita, Yukiyasu Okamura, Masamichi Hayashi, et al.Pageof 13